Carlos L. Arteaga, M.D. Departments of Medicine and Cancer Biology Breast Cancer Research Program Vanderbilt Ingram Comprehensive Cancer Center Vanderbilt University School of Medicine Are We About To Cure HER2- Are We About To Cure HER2- Positive Breast Cancer? Positive Breast Cancer?
43
Embed
Carlos L. Arteaga, M.D. Departments of Medicine and Cancer Biology Breast Cancer Research Program Vanderbilt Ingram Comprehensive Cancer Center Vanderbilt.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Carlos L. Arteaga, M.D.Departments of Medicine and Cancer Biology
Breast Cancer Research ProgramVanderbilt Ingram Comprehensive Cancer Center
Vanderbilt University School of Medicine
Are We About To Cure HER2-Are We About To Cure HER2-Positive Breast Cancer?Positive Breast Cancer?
Slamon et al. Science 237:177, 1987
Median Survival
HER2 overexpression 3 yrsHER2 normal 6-7 yrs
HER2/Neu (ErbB2) oncogene is associatedwith poor prognosis in breast cancer
HER2 protein overexpression (IHC)
HER2 geneamplification (Southern)
HER2 (ErbB2) is Oncogenic
HER2Control
HER2
Soft Agar
ErbB4HER4
EGFR/ErbB1HER1
ErbB2HER2
ErbB3HER3
Lig
ands
EC
IC
Ligands and Receptors of the HER (ErbB) family
100
100
100
44
82
33
36
59
24
48
79
28
EGFTGF
AmphiregulinHB-EGF
BetacellulinEpiregulin
? Heregulin(Neuregulin)
HeregulinHB-EGF
BetacellulinEpiregulin
Ligand binding
Tyr-Kinase
C-terminus
Some facts about the HER2 receptor network and HER2+
breast cancer
• HER2 is the most potent kinase and HER2-HER3 the most potent signaling dimer of this receptor network
• The main survival program activated by the HER (ErbB) network is the PI-3 kinase/Akt pathway
• The antibody trastuzumab and the tyrosine kinase inhibitor lapatinib are approved by the FDA for the treatment of HER2+ breast cancer
EGF30001: Phase III trial of paclitaxel ± lapatinibin first line or metastatic breast cancer
No benefit from lapatinib when analyzing the whole cohort
Benefit from the addition of lapatinib to paclitaxelwas significant in patients with HER2+ cancers
Adjuvant trastuzumab prolongs survival ofpatients with HER2+ breast cancer
Romond, Perez, Bryant, et al. NEJM 2005
07442776612171672Trastuzumab05937468911621679Control0133801145523793351No. at risk
0
% S
urv
ivin
g d
isease-f
ree
1 2 3 4 50
50
60
70
80
90
100
Years after randomization
Trastuzumab(133 events)
p<0.0001HR=0.48
Control(261 events)
87.1%85.3%
67.1%
75.4%
70
10
20
30
40
50
60
70
80
90
0
100
* Censors 4 patients who died due to causes other than breast cancer
10
20
30
40
50
60
0
Time (weeks)
CapecitabineLapatinib +
Capecitabine
0.00016P-value (log-rank, 1-sided)
69 (43%)45 (28%)Progressed or died*19.736.9Median TTP, wks
161160No. of pts
0.51 (0.35, 0.74)
Hazard ratio (95% CI)
% p
ati
en
ts f
ree f
rom
pro
gre
ssio
n*
Lapatinib prolongs progression-free survivalafter trastuzumab (Geyer et al. NEJM 2006)
Processing of trastuzumab-DM1 conjugate
Derivative ofMaytansine
Trastuzumab
Linker: MCC
• Normal-tissue target expression
• Fc-mediated uptake
• Non-specific uptake
HER2
Target-dependent cytotoxic activity
Trastuzumab-DM1 but not trastuzumab induces apoptosisand cell lysis and works in trastuzumab-resistant tumors
Lewis Phillips et al. Cancer Res. 68:9280, 2008
Krop et al. SABCS 2009 (late breaking abstract 710)
• HER2+ disease by FISH or 3+ IHC by local lab• Measurable disease by CT scan as per RECIST• Prior anthracycline, trastuzumab, taxane,
capecitabine and lapatinib therapy in any setting• Prior treatment with two HER2-directed regimens in the
metastatic setting• Documented progression on their most recent treatment
regimen• No history of significant cardiac disease; left ventricular
ejection fraction (LVEF) ≥50%• No history of Grade ≥3 hypersensitivity to trastuzumab or
toxicity requiring discontinuation • No Grade ≥3 peripheral neuropathy• No untreated or symptomatic brain metastases, or any
treatment for brain metastases within 3 months of first dose
• HER2+ disease by FISH or 3+ IHC by local lab• Measurable disease by CT scan as per RECIST• Prior anthracycline, trastuzumab, taxane,
capecitabine and lapatinib therapy in any setting• Prior treatment with two HER2-directed regimens in the
metastatic setting• Documented progression on their most recent treatment
regimen• No history of significant cardiac disease; left ventricular
ejection fraction (LVEF) ≥50%• No history of Grade ≥3 hypersensitivity to trastuzumab or
toxicity requiring discontinuation • No Grade ≥3 peripheral neuropathy• No untreated or symptomatic brain metastases, or any
treatment for brain metastases within 3 months of first dose
Key eligibility criteria
Clinical activity of trastuzumab-DM1 (n=110)
Krop I et al. SABCS 2009 (late breaking abstract 710)
Tumour response IRF(n=110)
Investigator(n=110)
Objective response rate, %(95% CI)
32.7(24.1–42.1)
30.0(22.0–39.4)
CR 0 1.8
PR 32.7 28.2
SD* 46.4 52.7
PD 18.2 13.6
UE 1.8 0.9
Missing 0.9 2.7
Clinical benefit rate, %(95% CI)
44.5(35.1–54.3)
40.0(31.1–49.3)
IRF, independent review facilityObjective response – CR or PR determined by two consecutive tumour assessments at least 28 days apartClinical benefit – objective response or SD maintained for at least 6 months
IRF, independent review facilityObjective response – CR or PR determined by two consecutive tumour assessments at least 28 days apartClinical benefit – objective response or SD maintained for at least 6 months
Implications• Even in advanced stages, HER2+ tumors
remain HER2-dependent
• Single agent anti-HER2 therapies do not inhibit the HER2 network completely
• Combinations of HER2-targeted drugs early in the treatment of HER2+ breast cancers is the rational way to go
• The optimal combination(s) of anti-HER2 agents up front may abrogate acquired resistance, shorten the duration of therapy, and dispense the need of chemotherapy
BT474 HR5
25016010575
P-Tyr
HER3
p85
lapatinib
+ +
p85 i.p.
+ lapatinib
P-HER3
HER3
P-Akt
Akt
In order to induce an antitumor effect, anti-HER2therapies should inhibit the PI3K/Akt pathway
Akt
Yakes et al. Cancer Res. 62:4132, 2002; Junttila et al. Cancer Cell 15:429, 2009
Tumour regressions only seen in heavily pretreated HER2+ patients
Best response and target lesion change (n=25)*
* One additional patient had complete regression of a single target lesion but overall response of progressive disease based on non-target lesions. One patient withdrawn for clinical progression without radiological assessment
Response rates for novel HER2-targeting agents after progression on trastuzumab
17-AAG Pertuzumab Neratinib
0
10
20
30
40
50
60
70
80
90
P<0.0001
Resp
onse
ra
tes
(%)
T-DM1
N=31 N=66N=45 N=112
Modi S et al, ASCO 2008; Gelmon KA et al, ASCO 2008; Swaby R et al, ASCO 2009; Burris HA et al, ESMO 2009
We have a good problem (many drugs) in HER2+ breast cancer – we are just learning how to combine them now
• Pertuzumab (anti-HER2 antibody)
• Irreversible HER2 kinase inhibitors (neratinib)
• HER3 antibodies (AMG-888, MM-121)
• PI3K inhibitors (GDC-0941, XL-147, BKM120)
• Akt inhibitors (MK-2206)
• IGF-IR inhibitors (R1507, MK-0646, OSI-906)
• HSP90 inhibitors
• Trastuzumab-DM1 (fusion toxin)
• Bevacizumab and other angiogenesis inhibitors
• MET, Src, and TGF inhibitors
Implications• There are several 2-drug combinations that can
aim at completely inhibiting the HER2 network and its output to PI3K– Lapatinib + trastuzumab– Trastuzumab + AMG-888– Trastuzumab + pertuzumab– Trastuzumab (or lapatinib) + a PI3K or a AKT inhibitor– Trastuzumb-DM1 + a PI3K or a AKT inhibitor
• Neoadjuvant therapy provides a space where these can be compared (using path CR as an endpoint)
• Some molecular phenotypes may be more sensitive to some specific combinations (i.e., tumors with PI3K pathway mutations)
• Although efficacy may be equivalent, toxicity and cost will be major differentiating factors